中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2015年
8期
206-207
,共2页
腹腔镜%米非司酮%子宫异位症
腹腔鏡%米非司酮%子宮異位癥
복강경%미비사동%자궁이위증
Laparoscopy%Mifepristone%Uterine endometriosis
目的:分析并研究腹腔镜手术后,米非司酮治疗子宫内膜异位症的临床效果。方法将我院在2013年4月~2014年4月收治的86例子宫内膜异位症腹腔镜手术后患者作为研究对象,将其随机分为观察组和对照组,每组各43例。对照组服用孕三烯酮,观察组服用米非司酮,观察并比较两组患者的治疗效果。结果两组患者的疼痛状况得到不同程度的缓解,观察组的完全治愈率为96.45%,对照组为82.14%, P<0.05,具有统计学意义;且观察组没有患者出现转氨酶升高的情况,对照组出现11例,P<0.05,具有统计学意义。结论腹腔镜手术后采用米非司酮治疗子宫内膜异位症有更好的效果,可以提高患者的治愈率,降低转氨酶升高率。
目的:分析併研究腹腔鏡手術後,米非司酮治療子宮內膜異位癥的臨床效果。方法將我院在2013年4月~2014年4月收治的86例子宮內膜異位癥腹腔鏡手術後患者作為研究對象,將其隨機分為觀察組和對照組,每組各43例。對照組服用孕三烯酮,觀察組服用米非司酮,觀察併比較兩組患者的治療效果。結果兩組患者的疼痛狀況得到不同程度的緩解,觀察組的完全治愈率為96.45%,對照組為82.14%, P<0.05,具有統計學意義;且觀察組沒有患者齣現轉氨酶升高的情況,對照組齣現11例,P<0.05,具有統計學意義。結論腹腔鏡手術後採用米非司酮治療子宮內膜異位癥有更好的效果,可以提高患者的治愈率,降低轉氨酶升高率。
목적:분석병연구복강경수술후,미비사동치료자궁내막이위증적림상효과。방법장아원재2013년4월~2014년4월수치적86례자궁내막이위증복강경수술후환자작위연구대상,장기수궤분위관찰조화대조조,매조각43례。대조조복용잉삼희동,관찰조복용미비사동,관찰병비교량조환자적치료효과。결과량조환자적동통상황득도불동정도적완해,관찰조적완전치유솔위96.45%,대조조위82.14%, P<0.05,구유통계학의의;차관찰조몰유환자출현전안매승고적정황,대조조출현11례,P<0.05,구유통계학의의。결론복강경수술후채용미비사동치료자궁내막이위증유경호적효과,가이제고환자적치유솔,강저전안매승고솔。
Objective To analyze and study of laparoscopic surgery, the clinical effect of mifepristone in treating endometriosis.Methods In our hospital in 86 cases of endometriosis of laparoscopic surgery in 2013 April to 2014 April were patients as the research object, then they were randomly divided into observation group and control group, 43 cases in each group. The control group taking pregnant three ketene, observation group was given mifepristone, the treatment effect of the two groups were observed and compared. ResultsTwo patients in pain conditions have different degree of ease, to observe fully cured group rate was 96.45%, 82.14% in the control group,P<0.05, with statistical significance, the observation group patients did not experience elevated transaminases, 11 occurred in the control group,P<0.05, with statistical significance.Conclusion Laparoscopic operation using mifepristone in treating endometriosis has better effect, can improve the cure rate of patients, reduce transaminase elevation rate, worthy of promotion in clinical use.